References S-238

- 1. Mkalaluh S, Szczeckowicz M, Karck M, Weyman A. Failed MitraClip therapy: surgical revision in high-risk patients. *J Cardiothorac Surg.* 2019;14:75
- Nishimura RA, O'Gara PT, Bavaria JE, Brindis RG, et al. 2019 AATS/ACC/ASE/SCAI/STS expert consensus systems of care document: a proposal to optimize care for patients with valvular heart disease: A joint report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2019;73(20):2609-2635.
- 3. Atianzar, KK, Zhang, MM, Newhart, ZZ, Gafoor, SS. Why did COAPT win while MITRA-FR failed? Defining the appropriate patient population for MitraClip. *Interv Cardiol*, 2019;14(1).
- 4. Nishimura RA, Otto CM, Bonow RO, et al. 2020 AHA/ACC Guideline for the management of patients with valvular heart disease: A report of the American college of cardiology/American heart association task force on clinical practice guidelines. *J Am Coll Cardiol*. 2021;70(2):252-289. 77(4):e25-197.
- 5. Kumar A, Al-Khafaji J, Shariff M, et al. Percutaneous mitral valve repair for secondary mitral valve regurgitation: A systematic review and metaanalysis. *Eur J Intern Med*.
- 6. Lung B, Armoiry X, Vahanian A, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. *Eur J Heart Fail*. 2019;21(12):1619-1627.
- 7. Buzzatti N, Van Hemelrijck M, Denti P, et al. Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: A propensity-weighted analysis. *J Thorac Cardiovasc Surg.* 2019;158(1):86-94.e1.
- 8. Thyregod HGH, Ihlemann N, Jorgensen TH, et al. Five-year clinical and echocardiographic outcomes from the nordic aortic valve intervention (notion) randomized clinical trial in lower surgical risk patients. 2019.
- 9. National Institute For Health And Care Excellence. Interventional procedure overview of valve-in-valve TAVI for aortic bioprosthetic valve dysfunction (IP

1013/2 [IPG653]). June 2019. https://www.nice.org.uk/guidance/ipg653/evidence/overview-final-pdf-6834685357. Accessed March 09, 2021.

- National Institute For Health And Care Excellence.Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction, Interventional procedures guidance [IPG653]. June 2019. https://www.nice.org.uk/guidance/ipg653. Accessed March 08, 2021.
- 11. Centers for Medicaid and Medicare Services. Decision Memo for Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R). https://www.cms.gov/medicare-coverage-database/details/nca-decisionmemo.aspx?NCAId=293&bc=ACAAAAAAQAAA&. Accessed March 08, 2021.
- 12. Hayes, Inc. Hayes Medical Technology Directory Report. Comparative effectiveness review of transcatheter aortic valve implantation (tavi) and surgical aortic valve replacement (SAVR) for Aortic Stenosis in Lower Risk Patients. Lansdale, PA: Hayes, Inc.; September, 2020.
- 13. Sengupta A, Yazdchi F, Alexis SL, et al. Reoperative mitral surgery versus transcatheter mitral valve replacement:a systematic review. *Journal of the American Heart Association*. 2021; 10:e0198
- 14. Urena M, Vahanian A, Brochet E, et al. Current indications for transcatheter mitral valve replacement using transcatheter aortic valves. 2021; 143(2):178-196
- 15.Hayes, Inc., Hayes Evidence Analysis Research Brief. Percutaneous mitral valve repair for secondary (functional) mitral valve regurgitation in high-risk adults - Executive Summary Lansdale, PA: Hayes, Inc. Published December 2020
- 16.Perl L, Kheifets M, Guido A, et al. Acute reduction in left ventricular function following transcatheter mitral edge to edge repair. *Journal of the American Heart Association*. 2023; 12:e029
- 17. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J.* 2022;43:561-632